Newstral
Article
jdsupra.com on 2019-02-14 19:13
Delaware Superior Court’s Complex Commercial Litigation Division Declines to Dismiss Delaware Attorney General’s Claims Against Opioid Makers
Related news
- Delaware Court of Chancery Declines to Dismiss Investment Firm from Stockholder Derivative Suitjdsupra.com
- Amgen’s Motion to Dismiss Genentech’s Complaint in the Delaware Mvasi Litigationjdsupra.com
- Delaware Court Of Chancery Declines To Dismiss Derivative Claims, Finding Wrongful Refusal Of Demand Adequately Pleadedjdsupra.com
- Delaware Takes the Lead in Litigation Reformjdsupra.com
- Delaware Chancery Court Refuses to Stay SPAC Class Action, Highlighting the Court’s Interest in SPAC Issues—and the Risk of Duplicative State and Federal SPAC Litigationjdsupra.com
- Delaware Court Of Chancery Declines To Dismiss Breach Of Fiduciary Duty Claims Against Nondirector Officer, Holding That Officers Owe A Caremark Duty Of Oversight jdsupra.com
- Delaware Litigation Developments Impacting Financial Advisorsjdsupra.com
- 2018 Delaware Corporate Law and Litigation Year In Reviewjdsupra.com
- 2019 Delaware Corporate Law and Litigation Year In Reviewjdsupra.com
- [Audio] Compliance Perspectives: Delaware Supreme Court’s Marchand v. Barnhill Decisionjdsupra.com
- LabCorp asks court to dismiss Delaware lawsuitbizjournals.com
- Delaware Supreme Court Upholds Lower Court’s Material Adverse Effect Findingjdsupra.com
- Judge Declines to Dismiss Menendez Chargesobserver.com
- Delaware - The New Black For Patent Litigation?jdsupra.com
- Delaware Court Approves Litigation Funding Agreementjdsupra.com
- Delaware Superior Court Narrows Jurisdiction In Mass Tort Litigationjdsupra.com
- Delaware Appraisal Litigation: Supreme Court Clarifies “Fair Value” Standardjdsupra.com
- USDC For Delaware Affirms Bankruptcy Court’s Denial Of Derivative Standingjdsupra.com
- Litigation Update: Genentech’s Motion to Dismiss Amgen’s Counterclaims Denied in Avastin Biosimilar Litigationjdsupra.com